2020
DKN-01 in combination with pembrolizumab in patients with advanced gastroesophageal adenocarcinoma (GEA): Tumoral DKK1 expression as a predictor of response and survival.
Klempner S, Bendell J, Villaflor V, Tenner L, Stein S, Naik G, Sirard C, Kagey M, Chaney M, Strickler J. DKN-01 in combination with pembrolizumab in patients with advanced gastroesophageal adenocarcinoma (GEA): Tumoral DKK1 expression as a predictor of response and survival. Journal Of Clinical Oncology 2020, 38: 357-357. DOI: 10.1200/jco.2020.38.4_suppl.357.Peer-Reviewed Original ResearchProgression-free survivalDisease control rateObjective response ratePD-L1 expressionAdvanced gastroesophageal adenocarcinomaGastroesophageal adenocarcinomaDKN-01Overall survivalDKK1 expressionGEA patientsMedian progression-free survivalImmune-suppressive tumor microenvironmentPhase 1b/2a studyKaplan-Meier methodSuppressive tumor microenvironmentPotential predictive biomarkersPredictors of responseDKK1 mRNA expressionDKK1 antibodyMedian OSFree survivalClinical benefitSurvival outcomesControl ratePredictive biomarkers
2017
A phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) for first-line therapy with advanced biliary tract cancer (BTC).
Eads J, Stein S, El-Khoueiry A, Manji G, Abrams T, Khorana A, Miksad R, Mahalingam D, Sirard C, Zhu A, Goyal L. A phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) for first-line therapy with advanced biliary tract cancer (BTC). Journal Of Clinical Oncology 2017, 35: 4075-4075. DOI: 10.1200/jco.2017.35.15_suppl.4075.Peer-Reviewed Original ResearchBiliary tract cancerAdvanced biliary tract cancerTreatment-emergent adverse eventsAdverse eventsPartial responseGrade 3/4 treatment-emergent adverse eventsAST/ALT elevationMonoclonal antibodiesDisease control rateEmergent adverse eventsMedian overall survivalFirst-line therapySerious adverse eventsDuration of responseHumanized monoclonal antibodyVEGF-C expressionInhibits cell invasionPromoter of metastasisDKN-01Median PFSALT elevationPrior regimensStable diseaseMedian durationProgressive disease
2016
698P Phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) with advanced biliary cancer (ABC)
Eads J, Stein S, El-Khoueiry A, Manji G, Abrams T, Khorana A, Miksad R, Mahalingam D, Sirard C, Zhu A, Goyal L. 698P Phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) with advanced biliary cancer (ABC). Annals Of Oncology 2016, 27: vi235. DOI: 10.1093/annonc/mdw371.90.Peer-Reviewed Original ResearchPD-016 Current results of a phase I study of DKN-01 in combination with paclitaxel (P) in patients (pts) with advanced DKK1+ esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ)
Ryan D, Murphy J, Mahalingam D, Strickler J, Stein S, Sirard C, Landau S, Bendell J. PD-016 Current results of a phase I study of DKN-01 in combination with paclitaxel (P) in patients (pts) with advanced DKK1+ esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ). Annals Of Oncology 2016, 27: ii108. PMCID: PMC4984164, DOI: 10.1093/annonc/mdw200.16.Peer-Reviewed Original ResearchPhase I study of DKN-01, an anti-DKK1 antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) with advanced biliary cancer.
Eads J, Goyal L, Stein S, El-Khoueiry A, Manji G, Abrams T, Landau S, Sirard C. Phase I study of DKN-01, an anti-DKK1 antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) with advanced biliary cancer. Journal Of Clinical Oncology 2016, 34: e15603-e15603. DOI: 10.1200/jco.2016.34.15_suppl.e15603.Peer-Reviewed Original Research